Regulus Therapeutics Inc.
RGLS
$2.06
$0.126.19%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | 33.26M | 1.02M | 8.31M | 6.04M | 20.51M |
| Gross Profit | -33.26M | -1.02M | -8.31M | -6.04M | -20.51M |
| SG&A Expenses | 4.07M | 3.86M | 3.95M | 2.79M | 2.54M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 13.75M | 15.21M | 12.26M | 8.83M | 8.30M |
| Operating Income | -13.75M | -15.21M | -12.26M | -8.83M | -8.30M |
| Income Before Tax | -12.79M | -14.06M | -11.04M | -8.47M | -8.06M |
| Income Tax Expenses | 0.00 | -- | 1.00K | -- | 0.00 |
| Earnings from Continuing Operations | -12.79M | -14.06M | -11.04M | -8.47M | -8.06M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -12.79M | -14.06M | -11.04M | -8.47M | -8.06M |
| EBIT | -13.75M | -15.21M | -12.26M | -8.83M | -8.30M |
| EBITDA | -13.66M | -15.12M | -12.17M | -8.75M | -8.22M |
| EPS Basic | -0.20 | -0.21 | -0.17 | -0.29 | -0.40 |
| Normalized Basic EPS | -0.12 | -0.13 | -0.11 | -0.18 | -0.25 |
| EPS Diluted | -0.20 | -0.21 | -0.17 | -0.29 | -0.40 |
| Normalized Diluted EPS | -0.12 | -0.13 | -0.11 | -0.18 | -0.25 |
| Average Basic Shares Outstanding | 65.50M | 65.47M | 64.47M | 28.75M | 20.22M |
| Average Diluted Shares Outstanding | 65.50M | 65.47M | 64.47M | 28.75M | 20.22M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |